Imagen de Portada
Código QR

Infliximab-Responsive Severe Ulcerative Colitis With Pyoderma Gangrenosum After IL-6 and IGF-1 Blockade.

Interleukin-6 (IL-6) and insulin-like growth factor-1 (IGF-1) are involved in immune regulation and tissue repair, but their combined effects on gastrointestinal mucosa remain unclear. We report a case of new-onset ulcerative colitis with pyoderma gangrenosum after sequential IL-6 and IGF-1 receptor...

Descripción completa

Publicado en:ACG Case Reports Journal Vol. 13; no. 6; pp. 1 - 5
Autores principales: Onishi, Shinobu, Otagiri, Shinsuke, Shinkai, Akihiro, Watanabe, Mika, Tanaka, Sho, Fujihata, Kenta, Aoyama, Keiya, Inoue, Ayano, Katsurada, Takehiko, Sakamoto, Naoya
Formato: case study pictorial Journal Article
Publicado: American College of Gastroenterology Jun2026
Acceso en línea:Ver este registro en EBSCOhost
Sumario:Interleukin-6 (IL-6) and insulin-like growth factor-1 (IGF-1) are involved in immune regulation and tissue repair, but their combined effects on gastrointestinal mucosa remain unclear. We report a case of new-onset ulcerative colitis with pyoderma gangrenosum after sequential IL-6 and IGF-1 receptor inhibition. The patient developed severe ulcerative colitis and pyoderma gangrenosum refractory to corticosteroids but showed rapid improvement after infliximab therapy, with endoscopic evidence of mucosal improvement. This case highlights a potential role for tumor necrosis factor-a (TNF-a) blockade in reversing severe immune dysregulation induced by IL-6 and IGF-1 inhibition.